Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter - PubMed (original) (raw)
. 2004 Mar 1;103(5):1641-6.
doi: 10.1182/blood-2003-07-2233. Epub 2003 Nov 6.
Affiliations
- PMID: 14604966
- DOI: 10.1182/blood-2003-07-2233
Free article
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
David Dingli et al. Blood. 2004.
Free article
Abstract
The Edmonston vaccine strain of measles virus (MV-Edm) propagates efficiently in a broad range of human tumor cells, killing them selectively. However, the oncolytic potency of MV-Edm in different human tumor xenograft therapy models is highly variable and there is no convenient way to map the distribution of virus-infected tissues in vivo. To enhance the oncolytic potency of MV-Edm against radiosensitive malignancies and to facilitate noninvasive imaging of infected tissues, we generated a recombinant MV-Edm encoding the human thyroidal iodide symporter (NIS). MV-NIS replicated almost as efficiently as unmodified MV-Edm, and human tumor cells efficiently concentrated radioiodine when infected with MV-NIS. Intratumoral spread of MV-NIS was noninvasively demonstrated by serial gamma-camera imaging of iodine-123 (123I) uptake both in MV-sensitive KAS-6/1 myeloma xenografts, which regressed completely after a single intravenous dose of MV-NIS, and in MM1 myeloma xenografts, which were unresponsive to MVNIS therapy. However, MV-resistant MM1 tumors regressed completely when 131I was administered 9 days after a single intravenous injection of MV-NIS (radiovirotherapy). 131I alone had no effect on MM1 tumor growth. While the potential hematopoietic toxicity of this new therapy requires further evaluation, image-guided radiovirotherapy is a promising new approach to the treatment of multiple myeloma, an incurable but highly radiosensitive plasma cell malignancy. Testing in other radiosensitive cancers is warranted.
Similar articles
- Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.
Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C, Studebaker AW. Hutzen B, et al. BMC Cancer. 2012 Nov 7;12:508. doi: 10.1186/1471-2407-12-508. BMC Cancer. 2012. PMID: 23134812 Free PMC article. - Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Msaouel P, et al. Mol Ther. 2009 Dec;17(12):2041-8. doi: 10.1038/mt.2009.218. Epub 2009 Sep 22. Mol Ther. 2009. PMID: 19773744 Free PMC article. - Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL. Reddi HV, et al. Cancer Gene Ther. 2012 Sep;19(9):659-65. doi: 10.1038/cgt.2012.47. Epub 2012 Jul 13. Cancer Gene Ther. 2012. PMID: 22790962 - Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Msaouel P, et al. Curr Cancer Drug Targets. 2018;18(2):177-187. doi: 10.2174/1568009617666170222125035. Curr Cancer Drug Targets. 2018. PMID: 28228086 Free PMC article. Review. - Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P, Dispenzieri A, Galanis E. Msaouel P, et al. Curr Opin Mol Ther. 2009 Feb;11(1):43-53. Curr Opin Mol Ther. 2009. PMID: 19169959 Free PMC article. Review.
Cited by
- Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H, Peng KW, Russell SJ. Li H, et al. Hum Gene Ther. 2012 Mar;23(3):295-301. doi: 10.1089/hum.2011.128. Epub 2012 Jan 11. Hum Gene Ther. 2012. PMID: 22235810 Free PMC article. - CRISPR/Cas9-mediated introduction of the sodium/iodide symporter gene enables noninvasive in vivo tracking of induced pluripotent stem cell-derived cardiomyocytes.
Ostrominski JW, Yada RC, Sato N, Klein M, Blinova K, Patel D, Valadez R, Palisoc M, Pittaluga S, Peng KW, San H, Lin Y, Basuli F, Zhang X, Swenson RE, Haigney M, Choyke PL, Zou J, Boehm M, Hong SG, Dunbar CE. Ostrominski JW, et al. Stem Cells Transl Med. 2020 Oct;9(10):1203-1217. doi: 10.1002/sctm.20-0019. Epub 2020 Jul 23. Stem Cells Transl Med. 2020. PMID: 32700830 Free PMC article. - Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy.
Tutter M, Schug C, Schmohl KA, Urnauer S, Kitzberger C, Schwenk N, Petrini M, Zach C, Ziegler S, Bartenstein P, Weber WA, Multhoff G, Wagner E, Lindner LH, Nelson PJ, Spitzweg C. Tutter M, et al. Mol Ther. 2021 Feb 3;29(2):788-803. doi: 10.1016/j.ymthe.2020.10.009. Epub 2020 Oct 15. Mol Ther. 2021. PMID: 33068779 Free PMC article. - The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications.
Tsang JJ, Atkins HL. Tsang JJ, et al. Oncolytic Virother. 2015 Jan 23;4:13-23. doi: 10.2147/OV.S45525. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512666 Free PMC article. Review. - Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.
Bray M, Di Mascio M, de Kok-Mercado F, Mollura DJ, Jagoda E. Bray M, et al. Antiviral Res. 2010 Nov;88(2):129-142. doi: 10.1016/j.antiviral.2010.08.005. Epub 2010 Aug 13. Antiviral Res. 2010. PMID: 20709111 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical